NEWS HIGHLIGHTSMedia Articles Related to Namenda (Memantine)
New Neuroimaging Analysis Technique Identifies Impact Of Alzheimer's Disease Gene In Healthy Brains
Source: Genetics News From Medical News Today [2009.11.19]
Brain imaging can offer a window into risk for diseases such as Alzheimer's disease (AD). A study conducted at the University of Kansas School of Medicine demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD. The results of this study are published in the November 2009 issue of the Journal of Alzheimer's Disease.
Analyzing Structural Brain Changes In Alzheimer's Disease
Source: Medical Devices / Diagnostics News From Medical News Today [2009.11.18]
In a study that promises to improve diagnosis and monitoring of Alzheimer's disease, scientists at the University of California, San Diego have developed a fast and accurate method for quantifying subtle, sub-regional brain volume loss using magnetic resonance imaging (MRI). The study is published the week of November 16 in the Proceedings of the National Academy of Sciences (PNAS).
Special Issue Of Behavioural Neurology Focuses On Alzheimer's Disease
Source: MRI / PET / Ultrasound News From Medical News Today [2009.11.11]
With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense.
High Blood Pressure And Markers Of Inflammation In Blood More Common In Offspring Of Parents With Alzheimer's Disease
Source: Hypertension News From Medical News Today [2009.11.04]
High blood pressure, evidence of arterial disease and markers of inflammation in the blood in middle age appear more common in individuals whose parents have Alzheimer's disease than in individuals without a parental history of the condition, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Alzheimer's Disease: Home Safety Information
Source: MedicineNet Advance Medical Directives Specialty [2008.08.26]
Title: Alzheimer's Disease: Home Safety Information
Category: Diseases and Conditions
Created: 8/26/2008
Last Editorial Review: 8/26/2008
Published Studies Related to Namenda (Memantine)
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. [2009.07.24]
BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD...
Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. [2009.07]
OBJECTIVE: Evaluate the efficacy and tolerability of memantine (20, 30, and 40 mg/d) in the acute treatment of adults with bipolar I disorder hospitalized for mania... CONCLUSIONS: The response to memantine combined with its tolerability support conducting large-sized randomized controlled trials to investigate further the use of memantine monotherapy in the treatment of mania.
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. [2009.07]
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine in patients with PDD or DLB... INTERPRETATION: Patients with DLB or PDD might benefit from treatment with memantine, which was well tolerated. Large-scale studies are now required to confirm our preliminary findings. FUNDING: The Western Norway Regional Health Authority; H Lundbeck A/S.
Efficacy and safety of memantine in Lewy body dementia. [2009.07]
Lewy body dementia (LBD) is a progressive brain disease manifest as dementia and parkinsonism, along with psychotic and autonomic disorders. Although studies in recent years have demonstrated the positive effects of cholinesterase inhibitors in LBD, the search for therapeutic agents with other mechanisms of action remains relevant...
Randomized controlled trial of memantine in dementia associated with Parkinson's disease. [2009.06.15]
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine...
Clinical Trials Related to Namenda (Memantine)
Memantine and Intensive Speech-Language Therapy in Aphasia [Completed]
- Aphasia, the loss or impairment of language caused by brain damage, is one of the most
devastating cognitive impairments of stroke. Aphasia can be treated with combination of
speech-language therapy and drugs. Conventional speech-language therapy in chronic
aphasic subjects is of little help and several drugs have been studied with limited
success. Therefore other therapeutic strategies are warranted.
- Recent data suggest that drugs (memantine) acting on the brain chemical glutamate may
help the recovery of cognitive deficits, included language, in subjects with vascular
dementia. The present study examines the safety profile and efficacy of memantine paired
with intensive language therapy in subjects with stroke-related chronic aphasia (more
than 1 yr. of evolution).
Memantine Therapy for Multiple Sclerosis [Suspended]
To assess the efficacy of Memantine in improving the cognitive impairment in patients with
Multiple Sclerosis (MS)
Namenda to Prevent Post-Operative Delirium [Terminated]
Post Operative Delirium is a common and serious risk of surgery. Delirium, when it occurs is
associated with an increased risk of mortality, increase length of stay, and more adverse
outcomes in general, including increased risk of higher level of care required at discharge.
Namenda, which is currently approved for moderate or severe Alzheimer's disease has a unique
mechanism of action than other drugs for this condition. It may have the ability to protect
the brain from more severe consequences of hypoxia, or hypoglycemia. Hence it is being
looked at in this study to see if it can reduce the incidence and/or severity of delirium
post-operatively.
Memantine Treatment for Obsessive-Compulsive Disorder and Generalized Anxiety Disorder [Completed]
The objective of this study was to obtain preliminary open-label data on the efficacy and
tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic
profile, in individuals with OCD and individuals with GAD. Because glutamatergic
hyperactivity in frontal and frontal-subcortical circuits may play a role in the symptomatic
expression of OCD, and possibly GAD, agents that reduce glutamatergic neurotransmission
should provide unique anti-stress and anti-obsessional benefits. Memantine is a specific,
uncompetitive antagonist at the NMDA receptor that blocks sustained activation of the NMDA
receptor by high concentrations of glutamate under pathological conditions but rapidly leaves
the NMDA channel upon transient physiological activation by low concentrations of glutamate.
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease [Completed]
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible
patients will receive open-label treatment with rivastigmine capsules plus memantine tablets
as add on therapy. This study is designed to evaluate the safety and tolerability of add on
therapy with memantine to rivastigmine capsules in patients with probable AD (MMSE 10-20)
|
